Fosamax vs Prolia (Denosumab): Comparing, Switching, and Combining the Two

How Each Drug Actually Stops Bone Loss

Both drugs cut fracture risk, but through mechanisms that produce meaningfully different clinical consequences when you start, stop, or combine them.

Alendronate: Permanent Bone Binding

Alendronate is a nitrogen-containing bisphosphonate. After oral absorption, it binds permanently to hydroxyapatite in bone matrix and is released only during active bone resorption. Once inside an osteoclast, it inhibits farnesyl pyrophosphate synthase, triggering osteoclast apoptosis. [1]

Because alendronate accumulates in bone over years, stopping it does not produce a sharp loss of effect. Residual drug continues to suppress resorption for months to years after the last dose. This "drug holiday" effect is a defining feature of bisphosphonate pharmacology and has direct implications for sequencing therapy. The FDA-approved label for alendronate allows consideration of a drug holiday after 3-5 years in lower-risk patients. [2]

Denosumab: Reversible RANKL Blockade

Denosumab is a fully human monoclonal IgG2 antibody that binds RANKL (receptor activator of nuclear factor kappa-B ligand), preventing RANKL from activating RANK on osteoclast precursors. Without that signal, osteoclast formation, function, and survival are all suppressed. [3]

The effect is completely reversible. When the injection wears off at roughly 6 months, RANKL activity rebounds, osteoclasts return in large numbers, and bone resorption accelerates sharply. This rebound is not just a theoretical concern. A 2017 case series published in Osteoporosis International documented multiple vertebral fractures in patients who simply missed their denosumab injection by more than a few weeks. [4]

No drug holiday from denosumab is appropriate without a transition plan.

Fracture Efficacy: Reading the Trial Data Side by Side

FIT Trial (Alendronate)

The Fracture Intervention Trial enrolled 2,027 postmenopausal women with existing vertebral fractures. Alendronate 10 mg daily reduced morphometric vertebral fracture risk by 47% over 3 years (8.0% vs 15.0%, P<0.001). [5] Hip fracture risk fell by 51% in the same cohort.

The FIT Long-Term Extension (FLEX) followed women who had already completed 5 years of alendronate. Women who continued for a total of 10 years maintained vertebral fracture protection, though hip fracture benefit was less clear, supporting the concept of reassessing duration. [6]

FREEDOM Trial (Denosumab)

FREEDOM enrolled 7,808 postmenopausal women aged 60-90 with osteoporosis. Denosumab 60 mg subcutaneously every 6 months reduced new vertebral fractures by 68% over 36 months (2.3% vs 7.2%, P<0.001) and hip fractures by 40%. [7] Nonvertebral fracture risk fell by 20%.

The FREEDOM Extension followed participants for an additional 7 years, reaching 10 years total. Lumbar spine BMD continued to rise through year 10, reaching a mean 21.7% gain from baseline, with no evidence of a therapeutic ceiling. [8] This durability, contingent on uninterrupted dosing, is the strongest argument for long-term denosumab in very high-risk patients.

Head-to-Head: STAND and DECIDE Trials

No large fracture-endpoint trial has directly compared the two drugs, but BMD trials offer useful data. In the STAND trial (N=504), switching from alendronate to denosumab increased lumbar spine BMD by 3.0% at 12 months versus 1.8% with continued alendronate (P<0.001). [9] The DECIDE trial (N=504) showed similar additive BMD gains when switching to denosumab. [10]

Switching from Fosamax to Prolia: When and How

Appropriate Candidates for the Switch

Switching from alendronate to denosumab makes sense in three clinical scenarios. First, patients who sustain a fracture on alendronate despite adequate adherence. Second, patients with worsening BMD T-scores after 3-5 years of oral bisphosphonate therapy. Third, patients who cannot tolerate oral alendronate due to upper gastrointestinal adverse effects, which occur in roughly 10-15% of users. The American Association of Clinical Endocrinology 2020 osteoporosis guidelines support escalation to denosumab in patients with high ongoing fracture risk who have failed or are intolerant of bisphosphonates. [11]

How to Execute the Switch Safely

Timing is straightforward. Give the first denosumab 60 mg injection at the point when the next alendronate dose would have been due, or sooner if the patient has active disease progression. No washout period is needed. Because residual alendronate in bone continues to act during the RANKL-inhibited period, the combination briefly produces maximal suppression of bone turnover. [12] This is generally safe in patients with normal calcium homeostasis; however, hypocalcemia risk rises, so calcium (1,000-1,200 mg daily from diet plus supplement) and vitamin D (800-1,000 IU daily) must be confirmed before the injection.

What You Cannot Do: Stop Denosumab Without a Bridge

This is the most consequential clinical point in this article. A 2019 analysis published in the Journal of Bone and Mineral Research found that patients who discontinued denosumab without subsequent bisphosphonate therapy experienced rapid BMD loss that erased all gains within 12-24 months, and some developed multiple vertebral fractures in that window. [13]

The standard bridging protocol after stopping denosumab is a bisphosphonate, typically alendronate 70 mg weekly or zoledronic acid 5 mg IV annually, started within 6 months of the last denosumab injection. The Endocrine Society's 2019 clinical practice guideline states: "We recommend transitioning patients who discontinue denosumab to an alternative antiresorptive agent to prevent rapid bone loss and increased fracture risk." [14]

Combining Alendronate and Denosumab: The DATA Trial Rationale

Why Combine at All

The two drugs block bone resorption through completely different pathways. Alendronate poisons osteoclasts from within; denosumab prevents them from forming in the first place. Targeting both pathways simultaneously should suppress resorption more completely than either agent alone. The DATA (Denosumab And Teriparatide Administration) trial tested combination therapy as part of a broader anabolic-antiresorptive design, and the BMD results supported the additive hypothesis.

DATA Trial Results

The DATA trial (N=94) compared teriparatide alone, denosumab alone, and the combination. At 24 months, the combination of denosumab plus teriparatide produced lumbar spine BMD gains of 9.1% versus 6.2% for denosumab alone and 6.2% for teriparatide alone (P<0.001 for combination vs either monotherapy). [15] While the DATA trial did not test alendronate plus denosumab directly, it demonstrated the biological plausibility of dual antiresorptive/anabolic use.

For the alendronate-plus-denosumab combination specifically, a 12-month crossover study (N=28) showed that adding denosumab on top of existing alendronate therapy produced a further 4-5% BMD increase at the lumbar spine compared to alendronate alone. [16]

Who Might Receive Combination Therapy

The table below outlines the clinical profile of patients where combination alendronate-plus-denosumab therapy may be considered, pending shared decision-making and specialist input.

| Patient Feature | Supports Combination | |---|---| | T-score below -3.5 at hip or spine | Yes | | Two or more fragility fractures in past 2 years | Yes | | Fracture on denosumab monotherapy | Yes | | Age over 75 with high fall risk | Relative | | Renal impairment (eGFR <35) | Caution: alendronate not recommended | | Active dental disease or planned jaw surgery | Caution: both drugs carry ONJ risk |

Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) are class effects of both drug classes. Combining them does not appear to double ONJ risk in available data, but the evidence base is limited to small series; a 2021 review in the Journal of Clinical Endocrinology and Metabolism estimated ONJ incidence at 0.02-0.05% per year for outpatient osteoporosis doses of either agent. [17] Dental evaluation before starting either drug remains standard of care.

Tolerability, Monitoring, and Practical Administration

Alendronate Administration Requirements

Alendronate must be taken on an empty stomach with 8 ounces of plain water, followed by 30 minutes of upright posture before any food or other medication. Esophageal ulceration has been reported with improper administration, and the drug is contraindicated in patients with esophageal abnormalities or inability to stand for 30 minutes. [18] Renal impairment with eGFR below 35 mL/min/1.73m2 is also a contraindication per the FDA label.

Generic alendronate costs approximately $10-30 per month in the United States, making it the most affordable oral option in the osteoporosis armamentarium.

Denosumab Administration and Lab Monitoring

Denosumab 60 mg is injected subcutaneously in the upper arm, thigh, or abdomen every 6 months by a healthcare professional. Hypocalcemia is the most clinically significant acute adverse effect; pre-injection serum calcium should be checked, particularly in patients with vitamin D deficiency, renal impairment, or malabsorption syndromes. [19]

Patients must maintain adequate calcium and vitamin D intake throughout denosumab therapy. The manufacturer's prescribing information specifies at least 1,000 mg elemental calcium and 400 IU vitamin D daily, though most endocrinologists recommend 800-1,000 IU vitamin D in older women. FDA prescribing information for denosumab (Prolia) details full contraindications and warnings. [20]

Long-Term Safety: Atypical Femoral Fractures

Atypical femoral fractures represent a rare but real adverse effect of prolonged antiresorptive use. A large Swedish registry study (N=1,234 AFF cases) found bisphosphonate use for more than 5 years was associated with an odds ratio of 117 for AFF compared with no bisphosphonate use, though absolute risk remained below 1 per 1,000 patient-years. [21] Denosumab carries a similar signal. Thigh or groin pain in a patient on long-term antiresorptive therapy warrants bilateral femur X-rays before continuing therapy.

Sequencing Decisions: A Practical Clinical Summary

The sequence of therapy matters as much as the drug choice itself. Several patterns are well-supported by clinical evidence.

Alendronate first, then denosumab. This is the most common escalation pattern and is supported by the STAND trial data. It works well for patients who have had a partial response to bisphosphonates and need greater BMD gains. The switch can happen at any point once the clinical indication is clear.

Denosumab with a planned bisphosphonate bridge. Any patient starting denosumab should have an exit strategy documented at initiation. The American Society for Bone and Mineral Research task force recommends a single infusion of zoledronic acid 5 mg given 6 months after the last denosumab injection if long-term denosumab cannot be continued. [22]

Anabolic therapy before antiresorptive. For patients with T-score below -3.5 or very high fracture risk, current guidelines from the Endocrine Society suggest considering anabolic agents (teriparatide or abaloparatide) first, followed by antiresorptive consolidation. Following teriparatide with denosumab rather than alendronate preserves more of the BMD gains achieved, as shown in the DATA-Switch trial. [23]

Rebound Fracture Risk: The Clinical Detail Most Articles Understate

The rebound phenomenon after denosumab discontinuation deserves its own discussion because the risk is not marginal. A 2021 systematic review and meta-analysis (15 studies, N=2,089 patients) found that multiple vertebral fractures occurred in 3.0-7.1% of patients who discontinued denosumab without bisphosphonate bridging. [24] That figure is roughly 2-3 times the annual vertebral fracture rate in untreated high-risk patients, meaning the rebound can push fracture risk above the pre-treatment baseline.

Risk factors for severe rebound include: prior vertebral fracture before starting denosumab, longer duration of denosumab treatment (more than 4 years), and low baseline T-score. [25]

The clinical instruction is direct: if a patient on denosumab moves, loses insurance, misses an injection by more than 4 weeks, or wants to stop for any reason, a bisphosphonate must be prescribed immediately. Alendronate 70 mg weekly for at least 12 months is the minimum; zoledronic acid 5 mg IV may be more reliable for patients with adherence concerns. A 2022 prospective study in the Journal of Bone and Mineral Research confirmed that a single dose of zoledronic acid 6 months after the last denosumab injection prevented the BMD rebound seen in untreated controls over a 24-month follow-up period. [26]